AGLEのチャート
AGLEの企業情報
| symbol | AGLE |
|---|---|
| 会社名 | Aeglea BioTherapeutics Inc （アエグリア・バイオセラピュ―ティクス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 Aeglea BioTherapeutics Inc. is a biotechnology company which is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. The Company''s product pipeline includes AEB1102 AEB3103 AEB2109 and AEB4104. Its lead product candidate AEB1102 is engineered to degrade the amino acid arginine and is being developed to treat over two extremes of arginine metabolism including arginine excess in patients with Arginase I deficiency an IEM as well as some cancers which have shown to have a metabolic dependence on arginine. AEB1102 reduces blood arginine levels in nonclinical and oncology clinical studies. AEB3103 targets the degradation of the amino acid cysteine/cystine. AEB2109 targets the degradation of the amino acid methionine. AEB4104 targets the reduction of elevated levels of the amino acid homocystine associated with the IEM classical homocystinuria. アエグリア・バイオセラピュ―ティクスは米国のバイオテクノロジ―企業。先天性の代謝疾患やがん治療のための治療用酵素の開発に注力する。血液中でアルギニン、システイン、メチオニン、ホモシステインなどの特定のアミノ酸を分解することで、がん疾患などにおける、アミノ酸の血中濃度を正常値に導くことに焦点を置く。本社はテキサス州オ―スティン。 Aeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with rare and devastating metabolic diseases with limited treatment options. Aeglea's lead product candidate, pegzilarginase, is in a pivotal Phase 3 trial for the treatment of Arginase 1 Deficiency and has received both Rare Pediatric Disease and Breakthrough Therapy Designation. In the second quarter of 2020, the Company initiated a Phase 1/2 clinical trial of AGLE-177 for the treatment of Homocystinuria. AGLE-177 has also been granted Rare Pediatric Disease Designation. Aeglea has an active discovery platform focused on engineering small changes in human enzymes to have a big impact on the lives of patients and their families. |
| 本社所在地 | 901 S. MoPac Expressway Barton Oaks Plaza One Suite 250 Austin TX 78746 USA |
| 代表者氏名 | Armen B. Shanafelt Armen B. Shanafelt |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 512-942-2935 |
| 設立年月日 | 41609 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2016年 |
| 従業員数 | 43人 |
| url | www.aegleabio.com |
| nasdaq_url | https://www.nasdaq.com/symbol/agle |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -32.25900 |
| 終値（lastsale） | 9.63 |
| 時価総額（marketcap） | 211812158.16 |
| 時価総額 | 時価総額（百万ドル） 209.99560 |
| 売上高 | 売上高（百万ドル） 6.63100 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 137.80260 |
| 当期純利益 | 当期純利益（百万ドル） -31.89000 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Aeglea Bio Therapeutics Inc revenues increased 58% to $3.9M. Net loss increased 36% to $17.5M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development - Balancing val increase of 47% to $15.3M (expense) General and administrative - increase of 16% to $4.7M (expense). |
AGLEのテクニカル分析
AGLEのニュース
Aeglea BioTherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 2023/03/17 21:30:00 PR Newswire
AUSTIN, Texas, March 17, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced the company granted non-qualified…
Aeglea BioTherapeutics''s Return On Capital Employed Insights 2023/03/07 14:48:20 Benzinga
Aeglea BioTherapeutics (NASDAQ: AGLE ) brought in sales totaling $168 thousand during Q4 according to data provided by Benzinga Pro . However, earnings decreased 3.22%, resulting in a loss of $18.82 million. In Q3, Aeglea BioTherapeutics brought in $174 thousand in sales but lost $18.23 million in earnings. What Is ROCE? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company''s ROCE. A higher ROCE is generally representative of successful growth of a company and is a sign … Full story available on Benzinga.com
Aeglea BioTherapeutics (AGLE) Investor Presentation - Slideshow (NASDAQ:AGLE) 2023/03/06 17:56:41 Seeking Alpha
The following slide deck was published by Aeglea BioTherapeutics, Inc.
Aeglea BioTherapeutics GAAP EPS of -$0.99 beats by $0.03, revenue of $2.33M beats by $0.1M (NASDAQ:AGLE) 2023/03/02 13:33:45 Seeking Alpha
Aeglea BioTherapeutics press release (AGLE): FY GAAP EPS of -$0.99 beats by $0.03.Revenue of $2.33M (-87.6% Y/Y) beats by $0.1M.As of December 31, 2022, Aeglea had available cash,…
Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Program Updates 2023/03/02 12:01:00 Benzinga
Jeffrey Goldberg , experienced biotech executive, appointed president and CEO; further strengthened senior management team with appointments of chief medical officer and chief product officer $57.3 million of cash, cash equivalents, marketable securities, and restricted cash as of December 31, 2022 , which is expected to fund operations into the fourth quarter of 2023 AUSTIN, Texas , March 2, 2023 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE ), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced financial results for the fourth quarter and full year 2022, and provided program updates. "Since joining the company, I have been impressed by the programs and the potential impact that they may have on patient lives. In 2023, we are highly focused on execution, specifically the generation of data from our pegtarviliase Phase 1/2 clinical trial in Classical Homocystinuria and, assuming success with those data, preparations to advance into a potential pivotal trial," said Jeffrey Goldberg , president and chief executive officer of Aeglea. "We are also continuing to work with our partner Immedica Pharma AB to support the EMA [European Medicines Agency] review process for the Marketing Authorization Application for pegzilarginase for the treatment of Arginase 1 Deficiency.
Aeglea BioTherapeutics Announces Update to Corporate Structure to Increase Operational Efficiency | MarketScreener 2023/01/06 12:02:04 MarketScreener
Streamlining of organization to focus on near-term deliverables for pegtarviliase in Homocystinuria and long-term value creation Cortney Caudill, M.B.A., has been promoted to the newly created role… | January 6, 2023
Aeglea BioTherapeutics Announces Update to Corporate Structure to Increase Operational Efficiency 2023/01/06 12:01:00 PR Newswire
Streamlining of organization to focus on near-term deliverables for pegtarviliase in Homocystinuria and long-term value creation Cortney Caudill, M.B.A., has been promoted to the newly created role of chief product officer to increase focus and efficiency in the advancement of clinical…
As The Stock Falls By -90.53% Year-To-Date, Aeglea BioTherapeutics Inc. (NASDAQ: AGLE)’S Stock Continues To Progress In 2022 2022/12/31 20:00:00 Marketing Sentinel
During the last session, Aeglea BioTherapeutics Inc. (NASDAQ:AGLE)’s traded shares were 0.62 million, with the beta value of the company hitting 1.74. At the end of the trading day, the stock’s price was $0.45, reflecting an intraday gain of 25.99% or $0.09. The 52-week high for the AGLE share is $4.83, that puts it down … As The Stock Falls By -90.53% Year-To-Date, Aeglea BioTherapeutics Inc. (NASDAQ: AGLE)’S Stock Continues To Progress In 2022 Read More »
Was anything positive for Aeglea BioTherapeutics Inc. (AGLE) stock last session? 2022/12/28 13:16:00 US Post News
As of Tuesday, Aeglea BioTherapeutics Inc.’s (NASDAQ:AGLE) stock closed at $0.39, up from $0.36 the previous day. While Aeglea BioTherapeutics Inc. has overperformed by 8.07%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, AGLE fell by -90.88%, with highs and lows ranging from $4.83 to $0.34, […]
A stock that deserves closer examination: Aeglea BioTherapeutics Inc. (AGLE) 2022/12/12 12:40:00 US Post News
A share of Aeglea BioTherapeutics Inc. (NASDAQ:AGLE) closed at $0.38 per share on Friday, down from $0.38 day before. While Aeglea BioTherapeutics Inc. has underperformed by -0.90%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, AGLE fell by -89.61%, with highs and lows ranging from $4.83 […]
Is Aeglea BioTherapeutics Inc. (NASDAQ: AGLE) Stock On Course For Another Boom Or Bust? 2022/09/17 15:30:00 Marketing Sentinel
During the last session, Aeglea BioTherapeutics Inc. (NASDAQ:AGLE)’s traded shares were 0.36 million, with the beta value of the company hitting 1.63. At the end of the trading day, the stock’s price was $0.49, reflecting an intraday loss of -7.58% or -$0.04. The 52-week high for the AGLE share is $8.50, that puts it down … Is Aeglea BioTherapeutics Inc. (NASDAQ: AGLE) Stock On Course For Another Boom Or Bust? Read More »
Following A -7.79% Weekly Decline, Is It Still A Buy For Aeglea BioTherapeutics Inc. (NASDAQ: AGLE)? 2022/09/10 18:00:00 Marketing Sentinel
Aeglea BioTherapeutics Inc. (NASDAQ:AGLE)’s traded shares stood at 0.39 million during the last session, with the company’s beta value hitting 1.64. At the close of trading, the stock’s price was $0.49, to imply a decrease of -1.94% or -$0.01 in intraday trading. The AGLE share’s 52-week high remains $8.50, putting it -1634.69% down since that … Following A -7.79% Weekly Decline, Is It Still A Buy For Aeglea BioTherapeutics Inc. (NASDAQ: AGLE)? Read More »
Enthralling stocks: Tyme Technologies, Inc. (NASDAQ:TYME -12.92%), Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE -5.77%) 2022/09/07 01:17:33 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Enthralling stocks: Tyme Technologies, Inc. (NASDAQ:TYME -12.92%), Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE -5.77%) appeared first on Stocks Equity .
Where Do Analysts Think The Aeglea BioTherapeutics Inc. (NASDAQ: AGLE) Is Going 2022/09/05 13:30:00 Stocks Register
Aeglea BioTherapeutics Inc. (NASDAQ:AGLE) price closed lower on Friday, September 02, dropping -2.20% below its previous close. A look at the daily price movement shows that the last close reads $0.53, with intraday deals fluctuated between $0.51 and $0.5312. The company’s 5Y monthly beta was ticking 1.94. Taking into account the 52-week price action we … Where Do Analysts Think The Aeglea BioTherapeutics Inc. (NASDAQ: AGLE) Is Going Read More »
After A 1.66% Gain In Share Price, Is Aeglea BioTherapeutics Inc. (NASDAQ:AGLE) A Better Trade Than Others? 2022/09/02 15:00:00 Marketing Sentinel
In last trading session, Aeglea BioTherapeutics Inc. (NASDAQ:AGLE) saw 1.11 million shares changing hands with its beta currently measuring 1.80. Company’s recent per share price level of $0.53 trading at $0.01 or 1.66% at ring of the bell on the day assigns it a market valuation of $32.85M. That closing price of AGLE’s stock is … After A 1.66% Gain In Share Price, Is Aeglea BioTherapeutics Inc. (NASDAQ:AGLE) A Better Trade Than Others? Read More »